LJPC-501 is La Jolla’s proprietary formulation of synthetic human angiotensin II. Angiotensin II, the major bioactive component of the renin-angiotensin-aldosterone system, serves as one of the body’s central regulators of blood pressure. LJPC-501 is being developed for the treatment of patients with distributive or vasodilatory shock who remain hypotensive despite fluid and vasopressor therapy (catecholamines and/or vasopressin).
Mode of Action
Angiotensin II (ANGII), the major bioactive component of the renin-angiotensin-aldosterone system (RAAS System), serves as one of the body’s central regulators of blood pressure. The RAAS system along with the arginine-vasopressin system and the sympathetic nervous system make up the three major counter-regulatory systems the human body utilizes to manage blood pressure. ANGII is a naturally occurring peptide hormone that regulates blood pressure through activation of the ANGII type 1 receptor (AT1R). Through the AT1R, ANGII induces peripheral vasoconstriction, increases sodium and water retention, aldosterone release, and vasopressin release leading to increase in blood pressure.